Ontology type: schema:ScholarlyArticle
1999-10
AUTHORSPaul V. Woolley, Fuad S. Freiha, David C. Smith, Lynn Carlson, Janie Hofacker, Nancy Quinn, William Grove, Donald L. Trump
ABSTRACTPURPOSE: To assess the antitumor activity of the benzothiopyranoindazole CI-958 ¿5-[(2-aminomethyl)amino]-2-[2-(diethylamino)ethyl]-2H- [l]benzothiopyrano[4,3,2-cd]-indazol-8-ol trihydrochloride¿ in hormone-resistant prostate carcinoma, using an intravenous dose of 700 mg/m(2) every 3 weeks. PATIENTS AND METHODS: Patients eligible for this study had advanced prostate carcinoma that had failed hormonal treatment. Changes in an initially elevated prostate-specific antigen (PSA) level and regression of objectively measurable disease were used as response criteria. RESULTS: All 33 patients enrolled were evaluated. Of 30 with elevated PSA levels, 6 had a >50% decline maintained for >30 days; response durations ranged from 105 to 623 days. Eleven patients had objectively measurable disease; two had partial responses (lasting 316 and 461 days) consisting of shrinkage of retroperitoneal nodes and of masses surrounding the rectum and bladder. The survival of all responding patients ranged from 366 days to 709 days and the median survival of all patients was 12 months (range 1-23 + months). Neutropenia was common, but thrombocytopenia was not. Nonhematologic side effects included nausea, vomiting, anorexia, asthenia, and chills, but were usually mild. The drug caused phlebitis when given into peripheral veins and central venous administration is recommended. No consistent reductions in cardiac function were documented by sequential assessment of left ventricular ejection fractions. CONCLUSIONS: CI-958 has modest but definite antitumor activity in hormone-resistant prostate carcinoma. Its toxicities include neutropenia, nausea, vomiting, anorexia, asthenia, chills and phlebitis. More... »
PAGES511-517
http://scigraph.springernature.com/pub.10.1007/s002800051126
DOIhttp://dx.doi.org/10.1007/s002800051126
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1019461349
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/10550573
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antineoplastic Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Indazoles",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Neoplasm Staging",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Patient Selection",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prostate-Specific Antigen",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prostatic Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tomography, X-Ray Computed",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Failure",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"name": [
"University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
],
"type": "Organization"
},
"familyName": "Woolley",
"givenName": "Paul V.",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Stanford Medicine",
"id": "https://www.grid.ac/institutes/grid.240952.8",
"name": [
"Stanford University Medical Center, Palo Alto, CA 94304-2299, USA, US"
],
"type": "Organization"
},
"familyName": "Freiha",
"givenName": "Fuad S.",
"id": "sg:person.0100055227.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0100055227.19"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
],
"type": "Organization"
},
"familyName": "Smith",
"givenName": "David C.",
"id": "sg:person.015706665604.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015706665604.37"
],
"type": "Person"
},
{
"affiliation": {
"name": [
"Laurel Highlands Cancer Program, Conemaugh's Memorial Medical Center and Lee Hospital, Johnstown, PA 15905, USA, US"
],
"type": "Organization"
},
"familyName": "Carlson",
"givenName": "Lynn",
"type": "Person"
},
{
"affiliation": {
"name": [
"University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
],
"type": "Organization"
},
"familyName": "Hofacker",
"givenName": "Janie",
"id": "sg:person.0762522245.51",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762522245.51"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Stanford Medicine",
"id": "https://www.grid.ac/institutes/grid.240952.8",
"name": [
"Stanford University Medical Center, Palo Alto, CA 94304-2299, USA, US"
],
"type": "Organization"
},
"familyName": "Quinn",
"givenName": "Nancy",
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer (United States)",
"id": "https://www.grid.ac/institutes/grid.410513.2",
"name": [
"Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, MI 48105, USA, US"
],
"type": "Organization"
},
"familyName": "Grove",
"givenName": "William",
"type": "Person"
},
{
"affiliation": {
"name": [
"University of Pittsburgh Cancer Institute, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA, US"
],
"type": "Organization"
},
"familyName": "Trump",
"givenName": "Donald L.",
"id": "sg:person.0710021450.77",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710021450.77"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/0021-9681(61)90060-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1043596267"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00174154",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046492696",
"https://doi.org/10.1007/bf00174154"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/jm00384a021",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055945720"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1021/jm00403a009",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1055946405"
],
"type": "CreativeWork"
}
],
"datePublished": "1999-10",
"datePublishedReg": "1999-10-01",
"description": "PURPOSE: To assess the antitumor activity of the benzothiopyranoindazole CI-958 \u00bf5-[(2-aminomethyl)amino]-2-[2-(diethylamino)ethyl]-2H- [l]benzothiopyrano[4,3,2-cd]-indazol-8-ol trihydrochloride\u00bf in hormone-resistant prostate carcinoma, using an intravenous dose of 700 mg/m(2) every 3 weeks.\nPATIENTS AND METHODS: Patients eligible for this study had advanced prostate carcinoma that had failed hormonal treatment. Changes in an initially elevated prostate-specific antigen (PSA) level and regression of objectively measurable disease were used as response criteria.\nRESULTS: All 33 patients enrolled were evaluated. Of 30 with elevated PSA levels, 6 had a >50% decline maintained for >30 days; response durations ranged from 105 to 623 days. Eleven patients had objectively measurable disease; two had partial responses (lasting 316 and 461 days) consisting of shrinkage of retroperitoneal nodes and of masses surrounding the rectum and bladder. The survival of all responding patients ranged from 366 days to 709 days and the median survival of all patients was 12 months (range 1-23 + months). Neutropenia was common, but thrombocytopenia was not. Nonhematologic side effects included nausea, vomiting, anorexia, asthenia, and chills, but were usually mild. The drug caused phlebitis when given into peripheral veins and central venous administration is recommended. No consistent reductions in cardiac function were documented by sequential assessment of left ventricular ejection fractions.\nCONCLUSIONS: CI-958 has modest but definite antitumor activity in hormone-resistant prostate carcinoma. Its toxicities include neutropenia, nausea, vomiting, anorexia, asthenia, chills and phlebitis.",
"genre": "research_article",
"id": "sg:pub.10.1007/s002800051126",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isFundedItemOf": [
{
"id": "sg:grant.2688757",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1088364",
"issn": [
"0344-5704",
"1432-0843"
],
"name": "Cancer Chemotherapy and Pharmacology",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "44"
}
],
"name": "A phase II trial of CI-958 in patients with hormone-refractory prostate cancer",
"pagination": "511-517",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"5cb9deba13e0a024eabd46e23bc3a75d5d6a21663756da88e1b74080c0a19a5f"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"10550573"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"7806519"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s002800051126"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1019461349"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s002800051126",
"https://app.dimensions.ai/details/publication/pub.1019461349"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T01:07",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8697_00000512.jsonl",
"type": "ScholarlyArticle",
"url": "http://link.springer.com/10.1007%2Fs002800051126"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002800051126'
This table displays all metadata directly associated to this object as RDF triples.
198 TRIPLES
21 PREDICATES
47 URIs
35 LITERALS
23 BLANK NODES